Xenetic Biosciences Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
XBIO Nasdaq 8731 https://www.xeneticbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xenetic Biosciences Inc

Xenetic Biosciences (NASDAQ:XBIO) Is In A Good Position To Deliver On Growth Plans - May 15th, 2023 12:08 pm
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - May 12th, 2023 4:30 pm
Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update - May 11th, 2023 8:30 pm
Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development - May 4th, 2023 12:35 pm
Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison - May 3rd, 2023 12:35 pm
Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Apr 11th, 2023 12:30 pm
Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update - Mar 23rd, 2023 11:35 am
Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event - Mar 16th, 2023 12:05 pm
Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy - Jan 17th, 2023 1:05 pm
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th - Jan 11th, 2023 6:00 pm
Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event - Jan 5th, 2023 1:05 pm
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All - Dec 15th, 2022 11:05 am
This Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks Appropriate - Dec 1st, 2022 10:47 am
Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform - Nov 16th, 2022 1:35 pm
Xenetic Biosciences Third Quarter 2022 Earnings: Beats Expectations - Nov 12th, 2022 1:04 pm
Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 10th, 2022 12:05 pm
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Oct 11th, 2022 12:05 pm
Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board - Oct 4th, 2022 12:00 pm
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 7th, 2022 12:05 pm
Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update - Aug 12th, 2022 12:00 pm